Related references
Note: Only part of the references are listed.Boronic Acids as Probes for Investigation of Allosteric Modulation of the Chemokine Receptor CXCR3
Viachaslau Bernat et al.
ACS CHEMICAL BIOLOGY (2014)
What does the aromatic ring number mean for drug design?
Simon E. Ward et al.
EXPERT OPINION ON DRUG DISCOVERY (2014)
CXCR3 modulates glial accumulation and activation in cuprizone-induced demyelination of the central nervous system
Marius Krauthausen et al.
JOURNAL OF NEUROINFLAMMATION (2014)
Biased Agonism as a Mechanism for Differential Signaling by Chemokine Receptors
Sudarshan Rajagopal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
OPINION Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Terry Kenakin et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Emerging paradigms in GPCR allostery: implications for drug discovery
Denise Wootten et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
A Simple Method for Quantifying Functional Selectivity and Agonist Bias
Terry Kenakin et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3
D. J. Scholten et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3
Belinda Nedjai et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Synthesis and Application of the First Radioligand Targeting the Allosteric Binding Pocket of Chemokine Receptor CXCR3
Viachaslau Bernat et al.
CHEMMEDCHEM (2012)
Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation
Graeme O'Boyle et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Pharmacological Primer of Biased Agonism
Bradley T. Andresen
Endocrine Metabolic & Immune Disorders-Drug Targets (2012)
Opposing Roles for CXCR3 Signaling in Central Nervous System Versus Ocular Inflammation Mediated by the Astrocyte-Targeted Production of IL-12
Marius Krauthausen et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Functionally biased modulation of A3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers
Zhan-Guo Gao et al.
BIOCHEMICAL PHARMACOLOGY (2011)
CXCR3 ligands: redundant, collaborative and antagonistic functions
Joanna R. Groom et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Functional Selectivity and Biased Receptor Signaling
Terry Kenakin
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Quantifying Ligand Bias at Seven-Transmembrane Receptors
Sudarshan Rajagopal et al.
MOLECULAR PHARMACOLOGY (2011)
Therapeutic potential of β-arrestin- and G protein-biased agonists
Erin J. Whalen et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Teaching old receptors new tricks: biasing seven-transmembrane receptors
Sudarshan Rajagopal et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - a tale of conflict and conundrum
M. Mueller et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2010)
CXCR3, Inflammation, and Autoimmune Diseases
Stephanie Lacotte et al.
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY (2009)
The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design?
Timothy J. Ritchie et al.
DRUG DISCOVERY TODAY (2009)
AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties
Irina Kalatskaya et al.
MOLECULAR PHARMACOLOGY (2009)
Synthesis of novel 3-heterospiro[5.5]undecanes
Johannes Froehlich et al.
ARKIVOC (2009)
Towards small-molecule CXCR3 ligands with clinical potential
Maikel Wijtmans et al.
CHEMMEDCHEM (2008)
Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3
Michael Johnson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists
Stefania Storelli et al.
ARCHIV DER PHARMAZIE (2007)
Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer
Tonya C. Walser et al.
CANCER RESEARCH (2006)
CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis
JD Pan et al.
JOURNAL OF IMMUNOLOGY (2006)
New concepts in drug discovery: Collateral efficacy and permissive antagonism
T Kenakin
NATURE REVIEWS DRUG DISCOVERY (2005)
The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate Gαi-independent signaling and actin responses in human intestinal myofibroblasts
A Kuroumalis et al.
JOURNAL OF IMMUNOLOGY (2005)
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
C Watson et al.
MOLECULAR PHARMACOLOGY (2005)
CXCR3 and its ligands participate in the host response to Bordetella bronchiseptica infection of the mouse respiratory tract but are not required for clearance of bacteria from the lung
DP Widney et al.
INFECTION AND IMMUNITY (2005)
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-Chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro
K Maeda et al.
JOURNAL OF VIROLOGY (2004)
Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function
RA Colvin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Ligand-selective receptor conformations revisited: the promise and the problem
T Kenakin
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis
I Salomon et al.
JOURNAL OF IMMUNOLOGY (2002)
G protein-coupled receptor allosterism and complexing
A Christopoulos et al.
PHARMACOLOGICAL REVIEWS (2002)
Requirement of the chemokine receptor CXCR3 for acute allograft rejection
WW Hancock et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
